Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
about
Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virusDose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavirBarriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participantsPharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimenBrief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.Fosamprenavir calcium plus ritonavir for HIV infection.Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy.Drug interactions in the management of HIV infection: an update.Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimizationAntiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir.Induction of cytochrome P450 enzymes: a view on human in vivo findings.Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapyElectrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
P2860
Q34776424-ED0C6220-A698-4F47-8E44-C8D6E7F709BEQ34973838-472549BB-E084-46CB-B415-C3C579AE3031Q35156644-952FFBDA-F38A-4FF9-949D-3F4D86A8C945Q35758844-09D8943A-A665-43B5-A98B-3BC58FF0AB71Q36289127-1DEB55DE-A072-4987-BCDA-BF8D0B9E7C10Q36723780-35DF6DF6-4AAC-44D9-A78F-F097C2AA12EFQ36839698-6139EDD5-858B-4B03-9988-5872FB24BB6DQ36951993-2D1CEF82-C999-4BFE-8174-A566D0A66145Q37000733-51C131E0-586B-4C42-A1EA-118EFC842D56Q37298637-29093DFC-7FF3-4983-93BC-45416A359106Q37378110-09C15914-B682-449B-ACAD-785E2DE2E5E4Q37846672-1AC65963-7148-4292-9E9C-2B5DB31AFA1AQ38057372-C19C9C9B-3629-483D-9BF9-D350B17A3F68Q42085839-D4378E6F-3128-469D-8FA0-38853ED9001BQ43244207-EFA5E677-0E9A-4AB5-9BD1-2C1352266BBDQ43689055-BE1469B6-CBD3-48EC-95C3-C65F8B0510CCQ45382474-37C2A584-3112-41EA-B142-98FE37D51535Q46599509-C60209ED-72F7-4C66-ADE6-74DC1A31688EQ46682546-4BD0CC0B-9B91-4BC9-B421-B4BC9631D76A
P2860
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Combining fosamprenavir with l ...... : ACTG protocol A5143 results.
@ast
Combining fosamprenavir with l ...... : ACTG protocol A5143 results.
@en
type
label
Combining fosamprenavir with l ...... : ACTG protocol A5143 results.
@ast
Combining fosamprenavir with l ...... : ACTG protocol A5143 results.
@en
prefLabel
Combining fosamprenavir with l ...... : ACTG protocol A5143 results.
@ast
Combining fosamprenavir with l ...... : ACTG protocol A5143 results.
@en
P2093
P1433
P1476
Combining fosamprenavir with l ...... : ACTG protocol A5143 results.
@en
P2093
Angela Dm Kashuba
Ann C Collier
Camlin Tierney
Edward P Acosta
Emanuel N Vergis
Gerald F Downey
John W Mellors
Karin Klingman
Trevor R Scott
P304
P356
10.1097/00002030-200501280-00006
P407
P577
2005-01-01T00:00:00Z